Nazal

Description

The product is identified by the SPL Code 34089-3 and is packaged in a carton. The carton is visually represented by the image file "nazalcart.jpg".

Uses and Indications

This drug is indicated for the temporary relief of nasal congestion associated with the common cold, hay fever, or sinusitis.

There are no teratogenic or nonteratogenic effects reported for this medication.

Dosage and Administration

For adults and children aged 12 years and older, the recommended dosage is 1 or 2 sprays administered in each nostril, with a maximum frequency of every 6 hours.

In children under 12 years of age, the use of this medication is not advised unless specifically directed by a healthcare professional.

Contraindications

Use of this product is contraindicated in the following situations:

• The product should not be used for more than 3 days due to potential adverse effects associated with prolonged use.

• It is contraindicated in children under 12 years of age, as ingestion may lead to sedation.

Warnings and Precautions

For external use only. This product is contraindicated for use beyond three days and should not be administered to children under 12 years of age, as ingestion may lead to sedation.

Healthcare professionals should advise patients to consult a physician prior to use if they have any of the following conditions: heart disease, high blood pressure, thyroid disease, diabetes, or difficulty urinating due to prostate gland enlargement.

During the use of this product, it is imperative that patients do not exceed the recommended dosage. Users may experience temporary discomfort, which can manifest as burning, stinging, sneezing, or an increase in nasal discharge. It is important to note that sharing this container with others may facilitate the spread of infection. The product should be used strictly as directed, as frequent or prolonged use may lead to a recurrence or worsening of nasal congestion.

Patients should be instructed to discontinue use and seek medical advice if symptoms persist. Additionally, this product must be kept out of reach of children. In the event of an accidental overdose, immediate medical assistance should be sought or contact with a Poison Control Center is recommended.

Side Effects

Patients using this product may experience temporary discomfort, which can include burning, stinging, sneezing, or an increase in nasal discharge. It is important to note that this product is for external use only and should not be used for more than three days. Additionally, it is contraindicated for use in children under 12 years of age, as ingestion may lead to sedation.

The use of this container by more than one person may facilitate the spread of infection. Furthermore, frequent or prolonged use of the product may lead to a recurrence or worsening of nasal congestion.

Patients are advised to stop use and consult a doctor if symptoms persist. Prior to using this product, individuals with a history of heart disease, high blood pressure, thyroid disease, diabetes, or difficulty in urination due to enlargement of the prostate gland should seek medical advice.

In the event of an accidental overdose, it is crucial to seek medical assistance or contact a Poison Control Center immediately.

Drug Interactions

No specific drug interactions have been identified in the available data. Additionally, there are no reported interactions between the drug and laboratory tests. Therefore, no dosage adjustments or monitoring recommendations are necessary based on the current information.

Packaging & NDC

Below are the non-prescription pack sizes of Nazal (naphazoline hydrochloride). Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients under 12 years of age should not use this medication due to the potential risk of sedation if swallowed. Administration in this age group is only recommended when directed by a healthcare professional. Caution is advised when considering treatment options for children in this demographic.

Geriatric Use

There is no specific information regarding the use of this medication in geriatric patients, including dosage adjustments, safety concerns, or special precautions. Healthcare providers should exercise caution when prescribing this medication to elderly patients, as individual responses may vary. It is advisable to monitor these patients closely for any adverse effects or changes in efficacy.

Pregnancy

Pregnant patients and those who are breastfeeding should consult a healthcare professional prior to using this medication. The potential risks and benefits must be carefully weighed, as the effects on fetal outcomes and lactation are not fully established. It is essential for women of childbearing potential to seek medical advice to ensure safe use during pregnancy and lactation.

Lactation

Lactating mothers are advised to consult a health professional prior to using this medication. There is no specific data available regarding the excretion of this medication in breast milk or its effects on breastfed infants. Therefore, caution is recommended when administering this medication to lactating individuals.

Renal Impairment

Patients with renal impairment have no specific information regarding dosage adjustments, special monitoring, or safety considerations provided in the drug insert. Therefore, healthcare professionals should exercise caution when prescribing this medication to individuals with reduced kidney function, as the lack of data necessitates careful clinical judgment.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in relation to this drug. Consequently, there are no established dosage adjustments, special monitoring requirements, or precautions outlined for individuals with compromised liver function. It is recommended that healthcare providers exercise caution when prescribing this medication to patients with hepatic impairment, given the lack of data on its safety and efficacy in this population. Regular monitoring of liver function may be prudent in these cases, although specific parameters are not defined in the prescribing information.

Overdosage

In the event of an accidental overdose, it is imperative to seek immediate medical assistance or contact a Poison Control Center without delay. Prompt intervention is crucial to mitigate potential adverse effects associated with overdosage.

Healthcare professionals should be aware that the symptoms of overdose may vary depending on the specific substance involved. Therefore, a thorough assessment of the patient's condition is essential to determine the appropriate course of action.

Management of an overdose typically involves supportive care and symptomatic treatment. Continuous monitoring of the patient's vital signs and clinical status is recommended. In cases where specific antidotes are available, their administration should be considered based on the clinical scenario.

It is essential for healthcare providers to remain vigilant and prepared to implement emergency protocols in the event of an overdose, ensuring the best possible outcomes for affected individuals.

Nonclinical Toxicology

No teratogenic or non-teratogenic effects have been reported in the available nonclinical studies. Additionally, there is no information regarding animal pharmacology and toxicology. The absence of data limits the assessment of potential risks associated with the compound in these areas.

Postmarketing Experience

Postmarketing experience has indicated that the use of naphazoline hydrochloride may be associated with temporary discomfort, including symptoms such as burning, stinging, sneezing, or an increase in nasal discharge. Additionally, it has been observed that frequent or prolonged use of the product may lead to a recurrence or worsening of nasal congestion.

Patient Counseling

Healthcare providers should advise patients to keep this product out of reach of children to prevent accidental ingestion. In the event of an accidental overdose, patients should be instructed to seek medical help or contact a Poison Control Center immediately.

Patients should be informed that this product should not be used for more than three days. It is important to emphasize that this product is not recommended for children under 12 years of age, as it may cause sedation if swallowed. If symptoms persist, patients should be advised to stop use and consult a doctor.

When using this product, patients must not exceed the recommended dosage. They should be made aware that temporary discomfort such as burning, stinging, sneezing, or an increase in nasal discharge may occur. Additionally, patients should be cautioned that the use of this container by more than one person may spread infection.

Patients should use this product only as directed. It is crucial to inform them that frequent or prolonged use may lead to a recurrence or worsening of nasal congestion.

Healthcare providers should encourage patients to consult a doctor before use if they have any of the following conditions: heart disease, high blood pressure, thyroid disease, diabetes, or difficulty in urination due to enlargement of the prostate gland.

Storage and Handling

The product is supplied in a container that is filled to the proper level to ensure optimal spray action. It is essential to store the product in a controlled environment, maintaining a temperature range that supports its stability and efficacy. Special handling precautions should be observed to preserve the integrity of the container and its contents.

Additional Clinical Information

No further data are available.

Drug Information (PDF)

This file contains official product information for Nazal, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)